Nibalap 250 mg (Tablet)
Unit Price: ৳ 350.00 (1 x 12: ৳ 4,200.00)
Strip Price: ৳ 4,200.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lapatinib |
| Company | Aristopharma ltd |
Indications
- Indicated for advanced or metastatic breast cancer
- Indicated for postmenopausal women with hormone receptor-positive metastatic breast cancer
Pharmacology
- 4-anilinoquinazoline kinase inhibitor
- Inhibits EGFR and HER2 receptors
- Additive effect with 5-FU
- Non-cross-resistance with Trastuzumab
- Highly bound to albumin and alpha-1 acid glycoprotein
- Undergoes extensive metabolism by CYP3A4 and CYP3A5
- Terminal phase half-life of 14.2 hours
- Predominantly metabolized by CYP3A4/5
- Negligible renal excretion
Dosage & Administration
- Recommended dose of 1,250 mg once daily
- Administered orally in combination with Capecitabine or Letrozole
- Dose adjustment if hepatic impairment is present
- Caution when coadministered with strong CYP3A4 inhibitors or inducers
Interaction
- Inhibits CYP3A4, CYP2C8, and P-glycoprotein
- Interacts with Midazolam, Paclitaxel, and Digoxin
- Increased systemic exposure with Ketoconazole, decreased exposure with Carbamazepine
- Substrate of P-glycoprotein
- Potential interaction with acid-reducing agents
Contraindications
- Contraindicated in patients with known severe hypersensitivity
Side Effects
- Common adverse reactions include diarrhea, palmar-plantar erythrodysesthesia, nausea, rash, vomiting, and fatigue
Pregnancy & Lactation
- Potential fetal harm if administered during pregnancy
- Advised not to breastfeed during treatment
Precautions & Warnings
- May decrease left ventricular ejection fraction
- Hepatotoxicity observed in clinical trials
- Management and monitoring of diarrhea
- Associated with interstitial lung disease and pneumonitis
- Linked to QT prolongation and severe cutaneous reactions
Use in Special Populations
- Dose modification guidelines for cardiac events, hepatic impairment, diarrhea, and concomitant strong CYP3A4 inhibitors/inducers
Overdose Effects
- No known antidote for overdoses
- Maximum oral doses administered in clinical trials
- Supportive measures for treatment of overdose
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Store below 30°C in a dry place